Results 111 to 120 of about 53,097 (209)

Characteristics of Clinical Response in Patients With Chronic Myeloid Leukemia With an ABL1 In‐Frame Exon 4 Deletion: A Multicenter Retrospective Study

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction In‐frame Exon 4 deletion (p.L184_K274del) is a rare ABL1 splicing variant in chronic myeloid leukemia (CML), the clinical significance of which remains unclear. Methods We retrospectively analyzed seven chronic‐phase CML patients with this variant, identified by Sanger sequencing during routine monitoring of atypically slow ...
Yuto Kaneda, Nobuhiro Kanemura, Yoshikazu Ikoma, Takuro Matsumoto, Nobuhiko Nakamura, Hiroshi Nakamura, Senji Kasahara, Kenji Fukuno, Yutaka Tsukune, Tomoiku Takaku, Masahito Shimizu   +10 more
wiley   +1 more source

Glucose Transporter 1 in Health and Disease

MedComm, Volume 7, Issue 8, August 2026.
As the quintessential facilitator of basal glucose uptake, glucose transporter 1 (GLUT1) is indispensable for maintaining systemic energy homeostasis. This graphical abstract delineates the multidimensional landscape of GLUT1 in normal physiology. It highlights its tissue‐specific metabolic roles—from fueling erythrocytes and fetal development to ...
Yi Tai, Zhihao Chen, Yuping Zhu, Weidong Han   +3 more
wiley   +1 more source

Decoding the allosteric grammar of protein kinases: A dual‐stream framework integrating protein language models and energy landscape frustration analysis

Protein Science, Volume 35, Issue 8, August 2026.
Abstract The spatial and energetic encoding of allosteric regulatory sites remains a major challenge in structural biology, frequently representing a “blind spot” for sequence‐based artificial intelligence (AI) models. We present a protein language model (PLM)‐guided approach complemented by the energy landscape frustration analysis as a dual‐stream ...
Will Gatlin, Max Ludwick, Lucas Turano, Brandon Foley, Kamila Riedlová, Vít Škrhák, Marian Novotný, David Hoksza, Gennady M. Verkhivker   +8 more
wiley   +1 more source

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia

Biologics: Targets & Therapy, 2009
Radhakrishnan Ramchandren, Charles A SchifferDivision of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USAAbstract: The development of imatinib for the treatment of chronic myeloid leukemia (CML ...
Radhakrishnan Ramchandren, Charles A Schiffer   +1 more
doaj  

RCSB protein data Bank: Next‐generation advanced search for exploration of experimental structures and computed structure models

Protein Science, Volume 35, Issue 8, August 2026.
Abstract The Protein Data Bank (PDB), established in 1971, is the primary global, open‐access archive for experimentally determined 3D macromolecular structures (proteins, RNA, DNA). The research‐focused RCSB.org web‐portal provides access to these data alongside more than one million machine‐learning‐predicted structure models, greatly expanding the ...
Yana Rose, Ronald Brown, Maria Voigt, Charmi Bhikadiya, Sebastian Bittrich, Jose M. Duarte, Joan Segura, Rachel Kramer Green, Stephen K. Burley   +8 more
wiley   +1 more source

Differential Impact of Pharmacokinetic and Pharmacodynamic Variability on Response to Combination Therapy

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Interindividual variability (IIV) in drug response complicates both fixed‐dose design and individualized therapy. Understanding how pharmacokinetic (PK) and pharmacodynamic (PD) processes jointly shape this variability is essential, particularly in combination therapy, where multiple interacting pathways influence outcomes. This study employed
Kuteesa R. Bisaso, Ronald Kadada Karyaburo, Jackson K. Mukonzo, Ene I. Ette   +3 more
wiley   +1 more source

Chronotherapy in Hematological Malignancies: Evaluating the Rationale and Evidence

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Hematological malignancies remain one of the leading causes of morbidity and mortality despite advances in targeted therapies, immunotherapy, and stem cell transplantation. Emerging evidence indicates that treatment efficacy and toxicity depend not only on the choice of therapy but also on its timing relative to the patient's internal ...
Andrej Belančić, Marko Skelin, Yun Wah Lam, Almir Fajkić, Bruna Perkov‐Stipičin, Rossana Roncato, Ivan Krečak, Marko Lucijanić   +7 more
wiley   +1 more source

3D Liver Fibrosis Models in Lab: A Novel Modality for Drug Screening

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Liver fibrosis is the common consequence of liver injury caused by a variety of chronic liver disorders. This condition leads to the development of more severe complications, particularly cirrhosis and hepatocellular carcinoma. Despite abundant studies, the fundamental cell and molecular mechanisms of liver fibrosis are still unknown.
Hani Keshavarz Alikhani, Fatemeh Majidi, Mahsa Ghasemzad, Anastasia Shpichka, Anastasia Nestorova, Zahra Hendi, Elham Rismani, Daria Kuznetsova, Peter Timashev, Massoud Vosough, Abbas Piryaei   +10 more
wiley   +1 more source

Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications. [PDF]

Cancer Chemother Pharmacol
Rasmussen ASB, Rank CU, Christensen IJ, Weimann A, Hansen K, Thastrup M, Yang T, Lund TM, Wik HS, Vogt H, Norén-Nyström U, Vaitkeviciene G, Albertsen BK, Wehner PS, Als-Nielsen B, Andersen CL, Dalhoff K, Schmiegelow K.   +17 more
europepmc   +1 more source

Therapeutic success and epidemiological failure in hematology

HemaSphere, Volume 10, Issue 8, August 2026.
Pierre Sujobert
wiley   +1 more source